# MILMENT OFTHO INDUSTRIES AND ORS v. ALLERGAN INC

- **Citation:** [2004] Supp. 2 S.C.R. 586
- **Court:** Supreme Court of India
- **Decided:** 2004-05-07
- **Bench:** S.N. Varia Va, H.K. Sema
- **Source:** https://unisonlegal.in/judgment/supreme-court-of-india/milment-oftho-industries-and-ors-v-allergan-inc-20094
- **Pages:** 7

## Headnote

Food and Drug Control-Respondent Company manufacturing
pharmaceutical products in several countries-Suit for passing off in
C respect of mark 'OCUFLOX' against Indian Company claiming to be the
first user of the mark-Grant of interim injunction-However vacated later
on the ground that Indian company was the first one to introduce the
product--Division Bench of High Court holding that the company filing
suit being first in the market entitled to injunction-On appeal, Held : As
D it is not clear with regard to the first user of the mark, matter to be
examined on evidence and remitted to trial court-If found that company
filing suit had adopted the mark prior to its use by the Indian Company,
then entitled lo injunction and if not, injunction to be vacated and Indian
Company would be entitled to damages.
E
Respondent-pharmaceutical company has been manufacturing
and marketing pharmaceutical products in several countries. They
filed suit for passing off in respect of mark "OCUFLOX" used on a
medicinal preparation for eye care product against the appellantIndian pharmaceutical company. They claimed to be the first user of
F this mark in several countries since 1992 and their applications for
registration of the mark in several other countries including India were
pending. Appellants were selling "OCUFLOX" on a medicinal
preparation used for the treatment of the eye and the ear and their
application for registration of the mark OCUFLOX filed in 1993 is
G pending. The Court granted ad interim injunction to the respondents,
which was later vacated on the ground that the respondents' product
was not being sold in India and the appellants were the first one to
introduce the product in India. Respondents filed an appeal. High
Court allowed the appeal holding that the respondents were first in the
H market, thus entitled to injunction. Hence the present appeal.
MILMENT OFTHO INDUSTRIES v. ALLERGAN INC.
587
Disposing of the appeal, the Court
HELD : 1.1. Whilst considering the possibility of likelihood of
deception or confusion, particularly in the field of medicines which
nowadays is of an international character, Court has to keep in mind
A
the possibility that with the passage of time, some conflict may occur B
between the use of the mark by the applicant in India and the user by
the overseas company. If a mark in respect of a drug is associated with
the respondents worldwide and an identical mark in respect of a
similar drug is allowed to be sold in India it would lead to an anomalous
situation. However one note of caution must be expressed. The Court C
must ensure that public interest is in no way imperiled. Further, the
multinational corporations, who have no intention of coming to India
of introducing their product in India should not be allowed to throttle
an Indian Company by not permitting it to sell product in India, if the
Indian Company has genuinely adopted the mark and developed the
product and is first in the market. The ultimate test should be who is D
first in the market. (591-D-E; 591-G-H)
1.2. In the instant case, the marks in respect of pharmaceutical
products are the same. The mere fact that the respondents have not been
using the mark in India would be irrelevant if they were first in the world E
market. The Division Bench of High Court had relied upon material
which prima-facie shows that the respondents' product was advertised
before the appellants entered the field and concluded thatthe respondents
were first to adopt the mark. If that be so then no fault can be found with
the conclusion drawn by the Division Bench. According to the appellants, F
the respondents were not the firstto use the mark and there was no proof
that the respondents had adopted the mark and used the mark before
the appellants started using the mark in India. Therefore, the matter
requires to be examined on evidence and is remitted to the trial court.
However, injunction order is continued. Further if on evidence it is
found that the responde

## Text

A
B
MILMENT OFTHO INDUSTRIES AND ORS.
V.
ALLERGAN INC.
MAY 7, 2004
[S.N. VARIA VA AND H.K. SEMA, JJ.]
Food and Drug Control-Respondent Company manufacturing
pharmaceutical products in several countries-Suit for passing off in
C respect of mark 'OCUFLOX' against Indian Company claiming to be the
first user of the mark-Grant of interim injunction-However vacated later
on the ground that Indian company was the first one to introduce the
product--Division Bench of High Court holding that the company filing
suit being first in the market entitled to injunction-On appeal, Held : As
D it is not clear with regard to the first user of the mark, matter to be
examined on evidence and remitted to trial court-If found that company
filing suit had adopted the mark prior to its use by the Indian Company,
then entitled lo injunction and if not, injunction to be vacated and Indian
Company would be entitled to damages.
E
Respondent-pharmaceutical company has been manufacturing
and marketing pharmaceutical products in several countries. They
filed suit for passing off in respect of mark "OCUFLOX" used on a
medicinal preparation for eye care product against the appellantIndian pharmaceutical company. They claimed to be the first user of
F this mark in several countries since 1992 and their applications for
registration of the mark in several other countries including India were
pending. Appellants were selling "OCUFLOX" on a medicinal
preparation used for the treatment of the eye and the ear and their
application for registration of the mark OCUFLOX filed in 1993 is
G pending. The Court granted ad interim injunction to the respondents,
which was later vacated on the ground that the respondents' product
was not being sold in India and the appellants were the first one to
introduce the product in India. Respondents filed an appeal. High
Court allowed the appeal holding that the respondents were first in the
H market, thus entitled to injunction. Hence the present appeal.
MILMENT OFTHO INDUSTRIES v. ALLERGAN INC.
587
Disposing of the appeal, the Court
HELD : 1.1. Whilst considering the possibility of likelihood of
deception or confusion, particularly in the field of medicines which
nowadays is of an international character, Court has to keep in mind
A
the possibility that with the passage of time, some conflict may occur B
between the use of the mark by the applicant in India and the user by
the overseas company. If a mark in respect of a drug is associated with
the respondents worldwide and an identical mark in respect of a
similar drug is allowed to be sold in India it would lead to an anomalous
situation. However one note of caution must be expressed. The Court C
must ensure that public interest is in no way imperiled. Further, the
multinational corporations, who have no intention of coming to India
of introducing their product in India should not be allowed to throttle
an Indian Company by not permitting it to sell product in India, if the
Indian Company has genuinely adopted the mark and developed the
product and is first in the market. The ultimate test should be who is D
first in the market. (591-D-E; 591-G-H)
1.2. In the instant case, the marks in respect of pharmaceutical
products are the same. The mere fact that the respondents have not been
using the mark in India would be irrelevant if they were first in the world E
market. The Division Bench of High Court had relied upon material
which prima-facie shows that the respondents' product was advertised
before the appellants entered the field and concluded thatthe respondents
were first to adopt the mark. If that be so then no fault can be found with
the conclusion drawn by the Division Bench. According to the appellants, F
the respondents were not the firstto use the mark and there was no proof
that the respondents had adopted the mark and used the mark before
the appellants started using the mark in India. Therefore, the matter
requires to be examined on evidence and is remitted to the trial court.
However, injunction order is continued. Further if on evidence it is
found that the respondents had adopted the mark prior to the appellants G
doing so, they would be entitled to an injunction and if not so then, the
trial court would vacate the injunction and the appellants would be
entitled to damages. 1592-B-C; 592-D-F]
Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) PTC H
588
SUPREME COURT REPORTS [2004] SUPP. 2 S.C.R.
A 300 SC, relied on.
N.R. Dongre v. Whirlpool Corporation, (1996) 16 PTC 583, referred
to.
B
CIVIL APPELLATE JURISDICTION : Civil Appeal No. 5791 of
c
1998.
From the Judgment and Order dated 6.11.97 of the Calcutta High
Court in A.P.O. No. 78/97, G.A. No. 3907, C.S. No. 349/96.
Joseph Pookkatt and Prashant Kumar for the Appellants.
C.M. Lall, Ms. Shikha Sachdev, Navin Chawla and Nitesh Rana for
the Respondent.
D
The Judgment of the Court was delivered by
S.N. V ARIA VA, J. : This Appeal is against the Judgment of the
Calcutta High Court dated 6th November, 1997.
E
Briefly stated the facts are as follows:
The Appellants are an Indian Pharmaceutical company. The
Respondents are also a Pharmaceutical company which manufacture
pharmaceutical products in several countries. The Respondents filed a Suit
F for an injunction based on an action for passing off in respect of mark
"OCUFLOX" used on a medicinal preparation manufactured and marketed
by the Respondents. The Respondents claimed that they were· the prior
users of the mark OCUFLOX in respect of an eye care product containing
Ofloxacin and other compounds. They claimed that they first used this
Mark on 9th September, 1992, after which they mar-keted the product in
G other countries like Europe, Australia, South Africa and South America and
that they had obtained registration in Australia, Bolivia, Ecuador, Mexico,
Peru, South Africa, Canada and the United States of America. They
claimed that therfiad also applied for registration of the mark in several
other countriesqncluding India and that their applications were pending.
H The Appellants were selling "OCUFLOX" on a medicinal preparation
MILMENT OFTHO INDUSTRIES v. ALLERGAN INC. [S.N. VARIA VA, J.)
589
containing CIPROFLOXACIN HCL to be used for the treatment of the eye A
and the ear. They claim that they coined the word "OCUFLOX" by taking
the
prefix "OCU"
from
"OCULAR"
and
"FLOX"
from
"CIPROFLOXACIN" which is the basic constituent o~their product. The
Appellants were granted registration by the food and Drug Control
Administration on 25th August, 1993. They have also applied for registration B
of the mark OCUFLOX in September 1993. 'Theip1pplication is also
,,/f"'
"
pending.
On 18th December, 1996 the Respondents got an ad interim injunction.
This injunction however was vacated on 29th January, 1997. The single
Judge held that the Respondents' product was not being sold in India and C
the Appellants having introduced the product first in India, the Respondents
were not entitled·to an injunction.
The Appeal filed by the Respondents had been allowed by the
impugned Judgment. The impugned Judgment has taken note of the law D
laid down by this Court. It has been held that the Respondents were first
in the market and therefore they were entitled to an injunction.
The law on the subject is well settled by a number of decisions. It
is not necessary to set out all those decisions. It would suffice to refer to E
only two decisions.
In the case of N R. Dongre v. Whirlpool Corporation reported in
1996 (16) PTC 583, the Appellants got registered the mark "Whirlpool"
in respect of washing machines. The Whirlpool Corporation filed a suit for F
passing off action brought by the Respondents to restrain the Appellants
from manufacturing, selling, advertising or in any way using the trade mark
"Whirlpool" of their product. It was held that the passing off an action was
maintainable in law even against the registered owner of the trademark.
It was held that the name of"Whirlpool" was associated for long with the
Whirlpool Corporation and that its trans-border reputation extended to G
India. It was held that the mark "Whirlpool" gave an indication of the origin
of the goods as emanating from or relating to the Whirlpool Corporation.
It was held that an injunction was a relief in equity and was based on
equitable principles. It was held that the equity required that an injunction
be granted in favour of the Whirlpool Corporation. It was held that the H ·
590
SUPREME COURT REPORTS [2004] SUPP. 2 S.C.R.
A refusal of an injunction could cause irreparable injury to the reputation of
the Whirlpool Corporation, whereas grant of an injunction would cause no
significant' Injury to the Appellants who could sell their washing machines
merely by removing a small label bearing the name "Whirlpool".
B
In the case of Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd.
reported in 2001 PTC 300 (SC), the question was whether the mark
"Falicigo" and "Falcitab" were deceptively similar. The trial Court refused
interim injunction. The Appeal was also dismissed. This Court did not
interfere on the ground that the matter required evidence on merits but laid
down principles on which such cases were required to be decided. This
C Court held that in a passing off action for deciding the question of deceptive
similarity the following facts had to be taken into consideration:
"a) The nature of the marks i.e. whether the marks are word
marks or label marks or composite marks, i.e. both words and
D
label works.
E
F
G
b) The degree of resembleness between the marks, phonetically
similar and hence similar !n idea.
c) The nature of the goods in respect of which they are used as
trade marks.
d) The similarity in the nature, character and performance of the
goods of the rival traders.
e) The class of purchasers who are likely to buy the goods bearing
the marks they require, on their education and intelligence and a
degree of care they are likely to exercise in purchasing and/or
using the goods.
f) The mode of purchasing the goods or placing orders for the
goods, and
g) Any other surrounding circumstances which may be relevant
in the extent of dissimilarity between the competing marks."
H In respect of medicinal products it was held that exacting judicial scrutiny
MILMENT OFTHO INDUSTRIES v. ALLERGAN INC. [S.N. VARIAVA, J.]
591
is required ifthere was a possibility of confusion over marks on medicinal A
products because the potential harm may be far more dire than that in
confusion over ordinary consumer products. It was held that even though
certain products may not be sold across the counter, nevertheless it was
not uncommon that because of lack of competence or otherwise that
mistakes arise specially where the trade marks are deceptively similar. It B
was held that confusion and mistakes could arise even for prescription
drugs where the similar goods are marketed under marks which looked
alike and sound alike. It was held that physicians are not immune from
confusion or mistake. It was held that it was common knowledge that many
prescriptions are telephoned to the pharmacists and others are handwritten,
and frequently the handwriting is not legible. It was held that these facts C
enhance the chances of confusion or mistake by the pharmacists in filling
the prescription if the marks appear too much alike.
We are in full agreement with what has been laid down by this Court.
Whilst considering the possibility of likelihood of deception or confusion, D
in present times and particularly in the field of medicines, the Courts must
also keep in mind the fact that nowadays the field of medicine is of an
international character. The Court has to keep in mind the possibility that
with the passage of time, some conflict may occur between the use of the
mark by the Applicant in India and the user by the overseas company. The E
Court must ensure that public interest is in no way imperiled. Doctors
particularly eminent doctors, medical practitioners and persons or Companies
connected with medical field keep abrest of latest developments in
medicine and preparations worldwide. Medical literature is freely available
in this country. Doctors, medical practitioners and persons connected with F
the medical field regularly attend medical conferences, symposiums,
lectures etc. It must also be remembered that nowadays goods are widely
advertised in newspapers, periodicals, magazines and other media which
is available in the countty. This results in a product acquiring a worldwide
reputation. Thus, if a mark in respect of a drug is associated with the
Respondents worldwide it would lead to an anomalous situation if an G
identical mark in respect of a similar drug is allowed to be sold in India.
However one note of caution must be expressed. Multinational corporations,
who have no intention of coming to India or introducing their product in
India should not be allowed to throttle an Indian Company by not
permitting it to sell a product in India, if the Indian Company has genuinely H
592
SUPREME COURT REPORTS [2004] SUPP. 2 S.C.R.
A adopted the mark and developed the product and is first in the market. Thus
the ultimate test should be who is first in the market.
In the present case, the marks are the same. They are in respect of
pharmaceutical products. The mere fact that the Respondents have not been
B using the mark in India would be irrelevant if they were first in the world
market. The Division Bench had relied upon material which prima facie
shows that the Respondents product was advertised before the Appellants
entered the field. On the basis of that material the Division Bench has
concluded that the Respondents were first to adopt the mark. If that be so
C then no fault can be found with the conclusion drawn by the Division
Bench.
However, it was submitted on behalf of the Appellants that the
Respondents were not the first to use the mark. It was submitted that there
was no proof that the Respondents had adopted the mark and used the mark
D before the Appellants started using the mark in India. In our view, these
are matters which would require examination on evidence. Considering the
fact that for all these years, because of the injunction Order, the Appellants
have sold their product under some other name, the balance of convenience
is that the injunction order be continued and the hearing of the Suit be
E expedited. If on evidence it is proved that the Respondents had adopted
the mark prior to the Appellants doing so, on the settled law, then the
Respondents would become entitled to an injunction. However, if on
evidence it is shown that the Respondents had not adopted the mark prior
to its use in India by the Appellants then, undoubtedly, the trial Court
F would vacate the injunction. The trial Court would undoubtedly then assess
the damage which Appellants have suffered for having wrongly not been
allowed to use the mark for all these years.
With these directions, the Appeal stands disposed of. There will be
no order as to costs. The Suit stands expedited. The trial Court is requested
G to dispose of the Suit as early as possible and in any case within a period
of 6 months from today.
N.J.
Appeal disposed of.